AbbVie (ABBV)
(Delayed Data from NYSE)
$200.47 USD
-3.08 (-1.51%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $200.75 +0.28 (0.14%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$200.47 USD
-3.08 (-1.51%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $200.75 +0.28 (0.14%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
Centene (CNC) Beats Q4 Earnings & Revenues, Ups '18 View
by Zacks Equity Research
Centene's (CNC) fourth-quarter earnings were hurt by higher selling, general & administrative expenses.
Bristol-Myers (BMY) Beats on Q4 Earnings, Eliquis Impresses
by Zacks Equity Research
Bristol-Myers (BMY) beats estimates on both counts in the fourth quarter. Eliquis records solid sales.
The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex
Amgen (AMGN) Q4 Earnings & Sales Lag, 2018 Sales View Soft
by Zacks Equity Research
Amgen (AMGN) misses expectations for both earnings and sales and also issues a lower-than-expected sales guidance for 2018. Shares decline in after-hours trading.
AstraZeneca (AZN) Beats on Q4 Earnings, Guides for 2018
by Zacks Equity Research
AstraZeneca (AZN) beats earnings estimates in fourth quarter on higher product revenues.
5 Top Earnings Growth Stocks to Buy in February
by Tirthankar Chakraborty
We have shortlisted 5 top-rated stocks that have striking earnings growth and positive estimate revisions.
Gilead's (GILD) HCV Segment to Decline Further in Q4 Earnings?
by Zacks Equity Research
Gilead's HCV franchise is under significant pressure due to increasing competition and the decline in franchise sales is expected to impact fourth-quarter results.
Will Gilead (GILD) Disappoint Investors in Q4 Earnings?
by Zacks Equity Research
Biotech bigwig Gilead Sciences (GILD) Q4 results are expected to be adversely impacted by the decline in HCV market share.
Biotech Stock Roundup: AbbVie 4Q Results Impress, Ablynx to be Acquired by Sanofi
by Arpita Dutt
While companies like AbbVie (ABBV) were in focus on 4Q earnings results, Ablynx was in the news with the company agreeing to be acquired by French pharma giant, Sanofi.
Lilly (LLY) Beats on Q4 Earnings, Raises 2018 EPS Guidance
by Zacks Equity Research
Lilly (LLY) beats on earnings and sales in Q4 and raises EPS outlook for 2018, reflecting a positive impact of the U.S. tax reform.
Anthem (ANTM) Tops Q4 Earnings & Revenues, Issues '18 View
by Zacks Equity Research
Anthem (ANTM) reported strong fourth-quarter results on the back of solid performance across its segments.
The Zacks Analyst Blog Highlights: Bank of America, Citigroup, AbbVie, 3M, Starbucks and Halliburton
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bank of America, Citigroup, AbbVie, 3M, Starbucks and Halliburton
Drug/Biotech Stocks Q4 Earnings Due on Jan 31: LLY & VRTX
by Zacks Equity Research
Two pharma/biotech giants are scheduled to report earnings on Jan 31. Let's take a look at how the companies are placed ahead of the upcoming releases.
HCA Healthcare's (HCA) Q4 Earnings, Revenues Beat Estimates (Revised)
by Zacks Equity Research
HCA Healthcare's (HCA) strong fourth-quarter results were driven by significant growth in admissions.
Novartis' Lutathera Gets FDA Approval for Pancreatic Tumors
by Zacks Equity Research
Novartis' oncology portfolio gets a further boost with the FDA approval of Lutathera for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors.
Roche Hemophilia Drug Hemlibra Gets Positive CHMP Opinion
by Zacks Equity Research
Roche announced that it its hemophilia drug Hemlibra obtained a positive opinion from the Committee for Medicinal Products for Human Use in Europe.
AstraZeneca's Triple Combo COPD Inhaler Positive in Phase III
by Zacks Equity Research
AstraZeneca (AZN) announces positive top-line results from the phase III KRONOS study on the triple combination therapy PT010 for severe COPD patients.
Stock Market News for Jan 29, 2018
by Zacks Equity Research
All the three key U.S. indexes closed at record levels on Friday following better-than-expected earnings from Intel, AbbVie and Honeywell
Strength Seen in AbbVie (ABBV): Stock Soars 13.8%
by Zacks Equity Research
AbbVie (ABBV) saw a big move last session, as its shares jumped nearly 14% on the day, amid huge volumes.
AbbVie (ABBV) Soars on Q4 Results: Key Takeaways from the Earnings Call
by Arpita Dutt
With AbbVie (ABBV) surpassing expectations in the fourth quarter, here's a look at a few important takeaways from the company's conference call.
AbbVie (ABBV) Q4 Earnings Beat, 2018 View Raised, Shares Up
by Zacks Equity Research
AbbVie's (ABBV) Q4 earnings top estimates with revenues marginally beating the same. Sales of the company's lead marketed drug, Humira, also rise year over year.
A Spate of Q4 Earnings
by Zacks Equity Research
A Spate of Q4 Earnings
Q4 GDP Sub-3%, Q4 Earnings Roll On
by Mark Vickery
The first read for Q4 GDP reached 2.6%, lower than the consensus estimate of 2.9%.
AbbVie (ABBV) Q4 Earnings & Revenues Beat, Guidance Raised
by Zacks Equity Research
AbbVie's (ABBV) fourth-quarter 2017 earnings surpassed estimates with revenues marginally beating the same. Sales of its lead marketed drug Humira also increased compared with the year ago figure.
Novartis Gets Spark Therapeutics' Luxterna License Outside US
by Zacks Equity Research
Novartis has obtained the marketing rights for Luxterna oustide the United States thereby building upon its gene therapy treatments which includes Kymriah.